A recent example of this paradigm is the advent of viral-mediated gene therapy for one subtype of patients with LCA who have mutations in RPE65, while other LCA patients who have mutations in more than 15 other genes are still awaiting therapeutic breakthroughs.1–3. This evidence concerns the gene RPE65 and Leber congenital amaurosis.